According to the WHO, patients suffering from cataract were reaching 65 millions^a，and the disease has been the number one cause of blindness^b.

Inflammation and pain are two prevalent findings after ocular surgeries, including cataract surgery. Therefore, to control post-surgical inflammation and pain, corticosteroids are widely administrated as a core treatment. However, improper patient adherence to post-operative eye drop regimens, limited bioavailability of topical eye drops, increase of intraocular pressure and the negative impact of preservatives used in many of these eye drops, has made a genuine motive for novel therapies development for post-surgical care^c .

TO-O-1004 eye drops is in early stage of pre-clinical study.

Ref:
a.World report on vision. Geneva: WHO; 2019.
b. Lancet Glob Health 2021; 9: e144-60.
c. Comm Eye Health Vol. 28 No. 90 2015 pp 32-33